OBJECTIVES: Post-transplant patients have high risk of re-hospitalization, incurring relevant costs. The aim of this study is to analyze causes, resource use and costs of re-hospitalizations in a cohort of renal transplanted patients. METHODS: A longitudinal analysis of a government administrative database (Inpatient Information System-SIH/DATASUS) was performed from January 2004 to July 2009. The study cohort was all patients who had undergone kidney transplant at 7 of the main transplant hospitals in Brazil, in 2004. All patients were followed until July 2009. Demographic data (sex, age, type of donor), length of re-hospitalization, resource use and associated costs (in 2004 USD) were collected. RESULTS: A total of 1030 patients were eligible for the analysis. Mean age was 38.7 ± 14.5 years, 57.6% were male recipients and 49.6% of transplant procedures were from living donors. During the study period 2,168 hospitalizations occurred in 643 patients (62%), with a total cost of US$ 1,568,956. Most frequent causes of re-hospitalization were post-transplant surgical and clinical complications (40.1%) and graft rejection episodes (32.4%), accounting together for 76.9% (US$ 1,207,406) of total expenses. Hospital services (ICU/Ward days, operation room, equipments, etc) represent the most significant part of re-hospitalization costs (40.9%), followed by diagnostic/laboratory exams (24.2%), medicines (13.6%) and health professional fees (11.0%). Re-hospitalizations were concentrated in the first (39.6%) and second (24.0%) years following transplant, stabilizing in the fourth and fifth years around 9% (200 hospitalizations/year). Patients receiving grafts from deceased donors accounted for 68.4% of total costs, and average costs per re-hospitalization were statistically different between patients receiving grafts from deceased (US$ 778 ± 1,181) relative to living donors (US$ 632 ± 973) (p < 0.01). CONCLUSIONS: The majority of patients who underwent kidney transplant in 2004 were re-hospitalized at least once until July 2009. Costs associated with these rehospitalizations were concentrated in the first year post-transplant and in cadaveric renal transplant recipients.
PUK22 REJECTION EPISODES REQUIRING HOSPITALIZATION AFTER KIDNEY TRANSPLANT IN BRAZIL: A RETROSPECTIVE DATABASE STUDY OF THE BRAZILIAN PUBLIC HEALTH SYSTEM
Duro-Garcia V 1 , Abbud-Filho M 2 , Esmeraldo RM 3 , Asano E 4 , Nita M 4 , Carvalho F 4 , Dan S 5 , Donato BM 6 , Rahal E 4 , The KIT73 STUDY GROU P 4 1 Universidade Federal de Ciências da Saúde de Porto Alegre, UFCSPA, Porto Alegre, Rio Grande do Su, Brazil, 2 FAMERP/FUNFARME Medical University, São Jose do Rio Preto, São Paulo, Brazil, 3 Hospital Geral de Fortaleza, Fortaleza, Ceara, Brazil, 4 Bristol-Myers Squibb S/A, São Paulo, São Paulo, Brazil, 5 New BD Assessoria Empresarial LTDA, São Paulo, São Paulo, Brazil, 6 Bristol-Myers Squibb Co, Wallingford, CT, USA OBJECTIVES: Graft rejection episodes are important causes of hospitalization in post-kidney transplant patients. The aim of this study is to analyze the incidence of rejection episodes (REs) requiring hospitalization after renal transplant, associated resource use and costs for the Brazilian Public Health System. METHODS: This is a longitudinal study combining data from two government databases (Outpatient and Inpatient Information Systems-SIA/DATASUS and SIH/DATASUS) connected by deterministic linkage. Diagnosis of REs was done by International Classification of Diseases (ICD-10) indicated on hospitalization. Kidney transplant patients from 7 hospitals in Brazil in 2004 with at least one additional database record were followed for 60 months post-transplant. Duration of hospitalization, resource use and costs converted to 2004 USD of all REs were collected. Kaplan-Meier curves for the first episode categorized by type of donor were calculated. RESULTS: From 1044 kidney transplant patients recorded in the database, 797 (410 deceased and 387 living) were eligible to the analysis. Proportion of patients that have not experienced any RE at 12, 24, and 60 months were 73.2%; 69.6%; and 60.1% in the living group and 72.1%; 70.0% and 66.0% in the deceased group. Kaplan-Meier curves, average length of stay (10.1 ± 8.2 days in the living group and 8.9 ± 8.5 days in the deceased group) and costs (US$715 ± 874 in the living group and US$651 ± 1,012 in the deceased group) of REs hospitalizations were not statistically different (p > 0.05). Total hospitalization costs were US$480,585. Hospital services (ICU/Ward days, operation room, equipments, etc) represent the most significant portion of costs (43.1%), followed by diagnostic/laboratory tests (26.1%). Among transplant-related medications, tacrolimus, OKT3 and basiliximab accounted, respectively, for 4.4%, 2.2% and 1.1% of total expenses. CONCLUSIONS: A total of 73% of kidney transplanted patients did not have REs in the first year post-transplant. Type of donor does not seem to influence occurrence, costs or duration of hospitalization.
URINARY/KIDNEY DISORDERS -Patient-Reported Outcomes Studies

PUK23 ADHERENCE TO A GUIDELINE FOR ERYTHROPOIESIS STIMULATING AGENTS IN CHRONIC KIDNEY DISEASE
Yeh YC 1 , Clapp MD 2 , Churchill WW 3 , O'Day J 4 , Reddy P 1 1 Partners Healthcare, Needham, MA, USA, 2 Massachusetts General Hospital, Boston, MA, USA, 3 Brigham & Women's Hospital, Boston, MA, USA, 4 Faulkner Hospital, Jamaica Plain, MA, USA OBJECTIVES: Given recent safety as well as cost concerns, an evidence-based guideline for erythropoiesis stimulating agents (ESA) in chronic kidney disease (CKD) was developed across a seven-hospital system. The purpose of this analysis was to evaluate adherence to the guideline. Specific objectives were to assess: whether 1) optimal hemoglobin levels (10-12 g/dL) were achieved, 2) ferritin or transferrin saturation (TSAT) was measured; and 3) iron therapy was administered, when appropriate. METHODS: The Research Patient Data Registry, a repository comprised of over four million patients and 900 million inpatient and outpatient encounters, diagnoses, medications, laboratory tests and results, and other medical care served as the data source. Data were available for three hospitals, two academic medical centers and a community teaching hospital. Patients were eligible for inclusion if they had a diagnosis of CKD based on ICD-9 diagnosis code and received at least two doses of ESA within three months. The analysis timeframe was November 2007 to April 2008. RESULTS: During the 6-month period, 344 eligible patients were identified. Of these, 54% achieved target hemoglobin levels within three months of therapy initiation. Approximately 4% did not have hemoglobin measured within three months. In the remaining patients, the hemoglobin level was less than 10 g/dL or more than 12 g/dL in 17% and 26% of patients, respectively. In 15% of patients neither ferritin nor TSAT were assessed. Among those with a ferritin < 100 ng/mL, 9% did not receive iron supplementation. TSAT was recorded only in one patient. CONCLUSIONS: Approximately half of the patients achieved target hemoglobin levels, highlighting the difficulty in maintaining target hemoglobin. These data suggest that adherence to this guideline can be improved in hemoglobin and iron monitoring and with iron supplementation.
URINARY/KIDNEY DISORDERS -Health Care Use & Policy Studies
PUK24 THE IMPACT OF ADDING A RACIAL CASE MIX ADJUSTER TO MEDICARE DIALYSIS REMIBURSEMENT: CORRECTING A POTENTIAL BIAS
Mutell R 1 , Mayne T 1 , Krishnan M 1 , Nissenson A 2 1 DaVita Clinical Research, Minneapolis, MN, USA, 2 DaVita Inc., El Segundo, CA, USA In 2011, a new prospective payment system will be instituted for Medicare payments for dialysis. CMS analyses revealed that dialysis payments differ significantly by race, yet CMS has not proposed including a racial case mix adjuster (CMA). Initial analyses showed that the proposed payment system without a racial CMA produced significant underpayment in dialysis units serving large numbers of black patients. OBJECTIVES: Model the impact of adding a racial case mix adjuster on dialysis reimbursement to clinics serving black patients, including a geospatial mapping to understand regional impact. METHODS: We used the racial case mix weights reported by CMS (though not included as a CMA), as well as the projected payments under the current and proposed payment systems. We used updated census data on race on the county level for a national analysis, and actual race for analysis of only DaVita clinics. We calculated clinic-level change in reimbursement using race CMA weights, then lowered the base payment rate to offset the incremental costs associated with the race CMA. We then use geomapping to plot percentage change due to race CMA, and overall change in proposed payment, and differential between current payment and proposed payment with and without the racial CMA. RESULTS: Among the 4276 dialysis clinics analyzed, the addition of the race CMA increased payment in 1140 clinics and decreased payments in 1206 clinics; it increased payment by ≥2% in 292 clinics and decreased payment by ≥2% in 172 clinics. Without the race CMA, payment reductions of ≥ 10% were disproportionately seen in areas in the southeast and in large cities with high percentages of blacks. This was ameliorated by the addition of the race case mix adjuster. CONCLUSIONS: CMS should include a race CMA in the prospective payment system for dialysis.
PUK25 CASE MIX ADJUSTMENT: THE CONSEQUENCES OF DIVERGENCE IN ACCESS TO DATA
Mayne T, Burgess M, Weldon J DaVita Clinical Research, Minneapolis, MN, USA The proposed Medicare prospective payment system for dialysis includes 18 case mix adjusters, 17 of which only increase payment. CMS calculated these adjusters using several data sources, including Medicare paid claims, and reduced the base payment 22% to offset the associated incremental costs. OBJECTIVES: Determine the ability of a large dialysis organization to detect CMAs using all available data sources, and calculate the financial impact of differences in CMAs ascertained by unit data, versus those reported by CMS. METHODS: Four dialysis units were randomly selected in each of 20 geographic regions. CMAs were ascertained via chart reviews, electronic medical records, hospital discharge summaries, paper charts, health care professional
